Portal de Periódicos da CAPES

Artigo Acesso aberto Produção Nacional Revisado por pares

BIBTEX RIS

In Vitro Evolution of Itraconazole Resistance in Aspergillus fumigatus Involves Multiple Mechanisms of Resistance

2004; American Society for Microbiology; Volume: 48; Issue: 11 Linguagem: Inglês

10.1128/aac.48.11.4405-4413.2004

1098-6596

Márcia Eliana da Silva Ferreira, José Luiz Capellaro, Everaldo dos Reis Marques, Iran Malavazi, David S. Perlin, Steven Park, James B. Anderson, Arnaldo Lopes Colombo, Beth A. Arthington‐Skaggs, Maria Helena S. Goldman, Gustavo H. Goldman,

Microbial Natural Products and Biosynthesis

ABSTRACT We investigated the evolution of resistance to the antifungal drug itraconazole in replicate populations of Aspergillus fumigatus that were founded from a strain with a genotype of sensitivity to a single drug and then propagated under uniform conditions. For each population, conidia were serially transferred 10 times to agar medium either with or without itraconazole. After 10 transfers in medium supplemented with itraconazole, 10 itraconazole-resistant mutant strains were isolated from two populations. These mutant strains had different growth rates and different levels of itraconazole resistance. Analysis of the ergosterol contents of these mutants showed that they accumulate ergosterol when they are grown in the presence of itraconazole. The replacement of the CYP51A gene of the wild-type strain changed the susceptibility pattern of this strain to one of itraconazole resistance only when CYP51A genes with N22D and M220I mutations were used as selectable marker genes. Real-time quantitative reverse transcription-PCR was used to assess the levels of expression of the Afumdr1 , Afumdr2 , Afumdr3 , Afumdr4 , AtrF transporter, CYP51A , and CYP51B genes in these mutant strains. Most mutants showed either constitutive high-level expression or induction upon exposure of Afumdr3 , Afumdr4 , and AtrF to itraconazole. Our results suggest that overexpression of drug efflux pumps and/or selection of drug target site mutations are at least partially responsible for itraconazole resistance and could be considered mechanisms for the emergence of clinical resistance to this drug.